For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome

Hello. We're improving abcam.com and we'd welcome your feedback.

Hello. We're improving abcam.com and we'd welcome your feedback.

Infomation icon

We haven't added this to the BETA yet

New BETA website

New BETA website

Hello. We're improving abcam.com and we'd welcome your feedback.

Take a look at our BETA site and see what we’ve done so far.

Switch on our new BETA site

Now available

Search and browse selected products

  • A selection of primary antibodies

Purchase these through your usual distributor

In the coming months

  • Additional product types
  • Supporting content
  • Sign in to your account
  • Purchase online
United States
Your country/region is currently set to:

If incorrect, please enter your country/region into the box below, to view site information related to your country/region.

Call (888) 77-ABCAM (22226) or contact us
Need help? Contact us

  • My account
  • Sign out
Sign in or Register with us

Welcome

Sign in or

Don't have an account?

Register with us
My basket
Quick order
Abcam homepage

  • Research Products
    By product type
    Primary antibodies
    Secondary antibodies
    ELISA and Matched Antibody Pair Kits
    Cell and tissue imaging tools
    Cellular and biochemical assays
    Proteins and Peptides
    By product type
    Proteomics tools
    Agonists, activators, antagonists and inhibitors
    Cell lines and Lysates
    Multiplex miRNA assays
    Multiplex Assays
    By research area
    Cancer
    Cardiovascular
    Cell Biology
    Epigenetics
    Metabolism
    Developmental Biology
    By research area
    Immunology
    Microbiology
    Neuroscience
    Signal Transduction
    Stem Cells
  • Customized Products & Partnerships
    Customized Products & Partnerships

    Customized products and commercial partnerships to accelerate your diagnostic and therapeutic programs.

    Customized products

    Partner with us

  • Support
    Support hub

    Access advice and support for any research roadblock

    View support hub

    Protocols

    Your experiments laid out step by step

    View protocols

  • Events
    • Conference calendar
    • Cancer
    • Cardiovascular
    • Epigenetics & Nuclear signaling
    • Immunology
    • Neuroscience
    • Stem cells
    • Tradeshows
    • Scientific webinars
    Keep up to date with the latest events

    Full event breakdown with abstracts, speakers, registration and more

    View global event calendar

  • Pathways
    Cell signalling pathways

    View all pathways

    View all interactive pathways

Knock-out (KO) validation: confirming antibody specificity

Related

  • Antibody validation
    • How we validate our antibodies
      • Using KO validation to overcome poor specificity
        • Webinar: Antibody validation with KO technology
          • Webinar: Raising antibody validation standards with KO technology
            • Whitepaper: Raising antibody validation standards
              • Tackling the reproducibility crisis
                  • Cell lines and lysates
                    • KO cell lines
                      • KO cell lysates
                        • Fast track your research with KO cell lines
                          • Custom CRISPR cell engineering services

                            To ensure you have highly specific antibodies, we use KO-validation via CRISPR-Cas9 genome-editing, to deliver the reliable results that your research demands. 

                             ​

                            Contents

                            • Knock-out validation: the need and solution
                            • Knock-out validation: testing results
                            • Knock-out validated antibodies promise 
                            • Knock-out cell lines and lysates 


                            The need

                            Antibodies are amongst the most commonly used tools in life science and clinical research for the study of proteins and their functions within various biological pathways and diseases.

                            A good antibody exhibits target specificity and sensitivity, allowing it to identify the protein of interest even at low expression levels. However, an increasing number of studies have shown that not all antibodies are specific in this way, with many showing cross-reactivities with off-target proteins. This has led to the recognized issue of experimental irreproducibility.1 These non-specific antibodies result in wasted resources and compromise the advancement of science.2,3

                            The solution: knock-out validation

                            Knock-out (KO) validation is a robust technique used to confirm antibody specificity by testing the antibody of interest in a KO cell line or tissue that does not express the target protein.4 A specific antibody should yield no signal when tested in a KO cell line while giving the specific target protein signal in the wild-type (WT) cell line. In this way, KO validation serves as a true negative control to confirm antibody specificity to the protein of interest.4,5

                            At Abcam, we use an extensive library of human KO haploid cell lines to perform antibody validation. These KO cell lines are generated via CRISPR-Cas9 and certified via Sanger sequencing. This type of KO cell line provides a complete loss-of-function phenotype from a single allele KO and eliminates any masking of the knockout from a second allele seen in diploid cell models.6-8 

                            Knock-out validation testing results

                            When KO-validating our antibodies, we primarily use western blot to assess the results. A range of western blot outcomes can result from KO validation, and the following examples demonstrate how we deal with each situation at Abcam.

                            Specific antibody

                            • Result: The expected molecular weight (MW) band disappears in the KO sample.
                            • Next steps: KO-based specific data is added to the datasheet. The antibody is guaranteed for specificity via KO-validation. 

                            Figure 1. Cdk4 RabMAb® product (ab108357). The expected band at the correct MW disappears in the KO sample.

                            All lanes: Anti-Cdk4 rabbit monoclonal antibody [EPR4513] (ab108357) at 1/1000 dilution 

                            Lane 1: Wild-type HAP1 cell lysate
                            Lane 2: Cdk4 Knockout HAP1 cell lysate

                            Predicted band size: 34 kDa
                            Observed band size: 34 kDa

                            Loading control (red band):  Anti-beta Actin antibody (ab8226) at 1/1000 dilution

                            Secondary antibodies:
                            IR Dye 800 Goat anti-Rabbit IgG (H + L)
                            IR Dye 680 Goat anti-Mouse IgG (H + L)
                            both at 1/10,000 dilution

                            Partially specific antibody – ​extra bands

                            • Result: The expected MW band disappears in the KO sample, but extra bands are present at a distinct MW.
                            • Next steps: We add KO-based specificity data to the datasheet. Additional research and testing will be performed to identify the extra bands.

                            Figure 2. Cdk6 Mouse monoclonal product (ab54576). The expected band at the correct MW disappears in the KO sample; thus, the antibody recognizes its intended target. However, extra bands are also present in both WT and KO samples. This may be due to antibody cross-reactivity with other protein family members/isoforms or unrelated proteins.

                            All lanes:  Anti-Cdk6 antibody (ab54576) at 1/1000 dilution

                            Lane 1: Wild-type HAP1 cell lysate
                            Lane 2: Cdk6 Knockout HAP1 cell lysate

                            Predicted band size: 37 kDa
                            Observed band size: 37 kDa

                            Loading control (red band):  Anti-beta Actin antibody (ab8227) at 1/1000 dilution

                            Secondary antibodies:
                            IR Dye 800 Goat anti-Mouse IgG (H + L)
                            IR Dye 680 Goat anti-Rabbit IgG (H + L)
                            both at 1/10,000 dilution

                            Non-specific antibody – ​weak signal in the KO sample

                            • Result: The expected MW band still present in KO at a lower intensity compared to WT. A benchmark antibody resolves a target band in WT and no band in KO. 
                            • Next steps: We add KO-based specific data to the datasheet. Additional research and testing will be performed to identify the reasons behind the signal in the KO sample.

                            Figure 3. Akt1 RabMAb® product (ab32038). The expected band at the correct MW is present in the KO sample but at a lower intensity compared to WT sample. However, the antibody may be exhibiting cross-reactivity with other protein family members/isoforms which are present at the same molecular weight in the sample as the target protein.

                            All lanes:  Anti-Akt1 rabbit monoclonal antibody (ab32038) at 1/1000 dilution

                            Lane 1: Wild-type HAP1 cell lysate
                            Lane 2: Akt1 Knockout HAP1 cell lysate

                            Predicted band size: 55 kDa
                            Observed band size: 55 - 60 kDa

                            Loading control (red band):  Anti-beta Actin antibody (ab8226) at 1/1000 dilution

                            Secondary antibodies:
                            IR Dye 800 Goat anti-Rabbit IgG (H + L)
                            IR Dye 680 Goat anti-Mouse IgG (H + L)
                            both at 1/10,000 dilution

                            Non-specific antibody – signal in the KO sample

                            • Result: expected MW band still present in KO at the same intensity as WT. A bench-mark antibody resolves a target band in WT and no band in KO.
                            • Next steps: we remove the antibody from the catalog, and recommend an alternative antibody with confirmed target specificity.

                            Figure 4. Akt1 rabbit polyclonal product (ab91505). The expected MW band is still present in the KO at the same intensity as the WT. Use of a bench-mark antibody shows a target band in the WT and no band in KO samples.

                            All lanes:  Anti-Akt1 rabbit polyclonal antibody (ab91505) at 1:1000

                            Lane 1: Wild-type HAP1 cell lysate
                            Lane 2: Akt1 Knockout HAP1 cell lysate

                            Predicted band size: 55 kDa
                            Observed band size: 55 - 60 kDa

                            Loading control (red band):  Anti-beta Actin antibody (ab8226) at 1/1000 dilution

                            Secondary antibodies:
                            IR Dye 800 Goat anti-Rabbit IgG (H + L)
                            IR Dye 680 Goat anti-Mouse IgG (H + L)
                            both at 1/10,000 dilution

                            Non-specific antibody – no target band in both KO and WT samples

                            • Result: The antibody does not recognize the target band in both the WT and KO samples. A bench-mark antibody resolves a target band in WT and no band in KO. 
                            • Next steps: We remove the antibody from the catalog, and recommend an alternative antibody with confirmed specificity.

                            Knock-out validated antibodies: our promise

                            When you see the KO validated seal, you can trust that the antibody has not only been validated in the recommended applications and species, but its specificity has been confirmed through our in-house KO validation approach.

                            See our complete list of KO-validated antibodies.


                            Knock-out cell lines and lysates: edited and ready for you

                            The application of CRISPR-Cas9 technology has allowed us to develop an extensive range of KO cell lines and lysates, so that we can provide you with reliable antibodies, saving you time and money. Each KO cell line is individually cloned, validated by Sanger sequencing, and supplied with the parental WT control lysate to allow the biological impact of the knock-out to be assessed within a consistent cellular background.

                            ​See our complete list of knockout cell lysates

                            See our complete list of knockout cell lines


                            References

                            1. Bradbury A and Pluckthun A. Reproducibility: Standardize antibodies used in research. Nature. 518:27-29 (2015).
                            2. Baker M. Reproducibility crisis: Blame it on the antibodies. Nature. 521:274-276 (2015).
                            3. Mullane K, Enna SJ, Piette J, Williams M. Guidelines for manuscript submission in the peer-reviewed pharmacological literature. Biochem Pharmacol. 97(3):225-35 (2015).
                            4. Zhong Z, Sassi M, Heaton S, Koch S, De Block G, Conlon D, Lochead J, Dreja H, Munro M, Solache A, Hamilton B. Large-scale use of knockout validation to confirm antibody specificity. J Immunol 200 (1 Supplement) 120.18 (2018).
                            5. Bordeaux J, Welsh AW, Agarwal S, Killiam E, Baquero MT, Hanna JA, Anagnostou VK, Rimm DL. Antibody Validation. Biotechniques. 48(3):197–209 (2010).
                            6. Bürckstümmer T, Banning C, Hainzl P, Schobesberger R, Kerzendorfer C, et al. A reversible gene trap collection empowers haploid genetics in human cells. Nat Methods. 10(10):965-71 (2013).
                            7. Reiling JH, Clish CB, Carette JE, Varadarajan M, Brummelkamp TR, Sabatini DM. A haploid genetic screen identifies the major facilitator domain containing 2A (MFSD2A) transporter as a key mediator in the response to tunicamycin. Proc Natl Acad Sci U S A. 108(29):11756-65 (2011).
                            8. Carette JE, Guimaraes CP, Varadarajan M, Park AS, Wuethrich I, et al. Haploid genetic screens in human cells identify host factors used by pathogens. Science. 326(5957):1231-5 (2009).


                            Get resources and offers direct to your inbox Sign up
                            A-Z by research area
                            • Cancer
                            • Cardiovascular
                            • Cell biology
                            • Developmental biology
                            • Epigenetics & Nuclear signaling
                            • Immunology
                            • Metabolism
                            • Microbiology
                            • Neuroscience
                            • Signal transduction
                            • Stem cells
                            A-Z by product type
                            • Primary antibodies
                            • Secondary antibodies
                            • Biochemicals
                            • Isotype controls
                            • Flow cytometry multi-color selector
                            • Kits
                            • Loading controls
                            • Lysates
                            • Peptides
                            • Proteins
                            • Slides
                            • Tags and cell markers
                            • Tools & Reagents
                            Help & support
                            • Support
                            • Make an Inquiry
                            • Protocols & troubleshooting
                            • Placing an order
                            • RabMAb products
                            • Biochemical product FAQs
                            • Training
                            • Browse by Target
                            Company
                            • Corporate site
                            • Investor relations
                            • Company news
                            • Careers
                            • About us
                            • Blog
                            Events
                            • Tradeshows
                            • Conferences
                            International websites
                            • abcam.cn
                            • abcam.co.jp

                            Join with us

                            • LinkedIn
                            • facebook
                            • Twitter
                            • YouTube
                            • Terms of sale
                            • Website terms of use
                            • Cookie policy
                            • Privacy policy
                            • Legal
                            • Modern slavery statement
                            © 1998-2023 Abcam plc. All rights reserved.